Venetoclax was granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia in previously treated patients with the 17p deletion genetic mutation.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
